Module 1: Faculty Presentations

Emmanuel Antonarakis, MD, PhD

Abida W et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: Final results from the phase 2 TRITON2 study. Eur Urol 2023;[Online ahead of print]. Abstract

Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract

Smith MR et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol 2022;23(3):362-73. Abstract

Susan Slovin, MD, PhD

Chi KN et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023;41(18):3339-51. Abstract

Chi KN et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Genitourinary Cancers Symposium 2022;Abstract 12.

Clarke NW et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2023;Abstract LBA16.

Clarke NW et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9). Abstract

Pritchard CC et al. Inherited DNA-repair gene mutation in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. Abstract

Saad F et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ESMO 2022;Abstract 13570.

Neeraj Agarwal, MD, FASCO

Agarwal N et al. TALARPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2023;Abstract LBA17.

Cheng JH et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol 2023;[Online ahead of print]. Abstract

Fizazi K et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations. ASCO 2023;Abstract 5004.

Karim Fizazi, MD, PhD

Jani C et al. A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. Genitourinary Cancers Symposium 2023;Abstract TPS5110.

McKay R et al. Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE). Genitourinary Cancers Symposium 2022;Abstract 119.

Petrylak DP et al. CheckMate 9KD A2 final analysis: Nivolumab plus rucaparib for chemotherapy-naïve metastatic castration-resistant prostate cancer. ESMO 2022;Abstract 579MO.

Sandhu S et al. LuPARP: Phase 2 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer. ASCO 2023;Abstract 5005.

Yu EY et al. Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase 3 KEYLINK-010 study. ESMO 2022;Abstract 1362MO.

Module 2: Journal Club

Agarwal N et al. Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2). ASCO 2023;Abstract 5013.

Agarwal N et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 2022;18(4):425-36. Abstract

Antonarakis ES, Abida W. Combining poly(ADP)-ribose polymerase inhibitors with abiraterone in castration-resistant prostate cancer: Is biomarker testing necessary? J Clin Oncol 2023;41(18):3291-4. Abstract

Beije N et al. PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues. Eur Urol 2023;[Online ahead of print]. Abstract

Chi KN et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res 2023;29(1):81-91. Abstract

Flippot R et al. PARP inhibition, a new therapeutic avenue in patients with prostate cancer. Drugs 2022;82(7):719-33. Abstract

Hussain MH et al. BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects. ASCO 2022;Abstract 5018.

Lang J et al. Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). ESMO 2022;Abstract 1406P.

Matsubara N et al. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA. Clin Cancer Res 2023;29(1):92-9. Abstract

Roubaud G et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur J Cancer 2022;170:73-84. Abstract

Slovin SF et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2022;Abstract 98.

Swami U et al. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol 2022;12:966534. Abstract

Teply BA, Antonarakis ES. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: A spotlight on treatment combinations. Expert Rev Clin Pharmacol 2022;15(11):1293-304. Abstract

Truong H et al. Gene-based confirmatory germline testing following tumor-only sequencing of prostate cancer. Eur Urol 2023;83(1):29-38. Abstract